Cargando…
Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19
Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials reg...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361049/ https://www.ncbi.nlm.nih.gov/pubmed/33017904 http://dx.doi.org/10.1016/j.mehy.2020.110110 |